← Back to Search

Device

BEC Treatment for Pulmonary Embolism

Phase 1
Waitlist Available
Research Sponsored by Thrombolex, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up within 72 hours of initiation of r-tpa administration.
Awards & highlights

Study Summary

The Bashir™ Endovascular Catheter is a device intended for the localized infusion of therapeutic agents into the pulmonary artery and peripheral vasculature.

Eligible Conditions
  • Pulmonary Embolism

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~within 72 hours of initiation of r-tpa administration.
This trial's timeline: 3 weeks for screening, Varies for treatment, and within 72 hours of initiation of r-tpa administration. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Safety: Number of Participants With Major Bleeding Events

Trial Design

1Treatment groups
Experimental Treatment
Group I: BEC TreatmentExperimental Treatment2 Interventions
The Bashir™ Endovascular Catheter is a device intended for the localized infusion of therapeutic agents into the pulmonary artery.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
r-tPA
2019
Completed Phase 3
~120
The Bashir™ Endovascular Catheter
2019
Completed Phase 3
~120

Find a Location

Who is running the clinical trial?

Thrombolex, Inc.Lead Sponsor
1 Previous Clinical Trials
109 Total Patients Enrolled
1 Trials studying Pulmonary Embolism
109 Patients Enrolled for Pulmonary Embolism

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
First - In - Man Study to Assess the Safety and Feasibility of The Bashir™ Endovascular Catheter for the Treatment of Acute Pulmonary Embolism
2019. "First - In - Man Study to Assess the Safety and Feasibility of The Bashir™ Endovascular Catheter for the Treatment of Acute Pulmonary Embolism". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03927508.
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top